{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:10:29Z","timestamp":1788869429393,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00415-026-14124-1","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:31:23Z","timestamp":1788867083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ocrelizumab versus ofatumumab efficacy and safety after natalizumab discontinuation in multiple sclerosis: a retrospective real-world comparison\u00a0\u00a0"],"prefix":"10.1007","volume":"273","author":[{"given":"Veronica","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zanetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Margoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Nozzolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gattuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Viti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Petza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Guerrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"14124_CR1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14764","author":"G Vivekanandan","year":"2021","unstructured":"Vivekanandan G, Abubacker AP, Myneni R et al (2021) Risk of progressive multifocal leukoencephalopathy in multiple sclerosis patient treated with natalizumab: a systematic review. Cureus. https:\/\/doi.org\/10.7759\/cureus.14764","journal-title":"Cureus"},{"issue":"1","key":"14124_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/19418744211031360","volume":"12","author":"JD Lee","year":"2022","unstructured":"Lee JD, Chen T (2022) Natalizumab rebound in multiple sclerosis. Neurohospitalist 12(1):197\u2013198. https:\/\/doi.org\/10.1177\/19418744211031360","journal-title":"Neurohospitalist"},{"key":"14124_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1086028","volume":"14","author":"P Santiago-Setien","year":"2023","unstructured":"Santiago-Setien P, Barqu\u00edn-Rego C, Hern\u00e1ndez-Mart\u00ednez P et al (2023) Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: a 96-week follow-up pilot study. Front Immunol 14:1086028. https:\/\/doi.org\/10.3389\/fimmu.2023.1086028","journal-title":"Front Immunol"},{"issue":"14","key":"14124_CR4","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1177\/1352458520927631","volume":"26","author":"SN Levin","year":"2020","unstructured":"Levin SN, Ezuma C, Levine L et al (2020) Switching from natalizumab to ocrelizumab in patients with multiple sclerosis. Mult Scler J 26(14):1964\u20131965. https:\/\/doi.org\/10.1177\/1352458520927631","journal-title":"Mult Scler J"},{"issue":"5","key":"14124_CR5","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/1352458520946017","volume":"27","author":"CR Mancinelli","year":"2021","unstructured":"Mancinelli CR, Scarpazza C, Cordioli C et al (2021) Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab. Mult Scler J 27(5):790\u2013794. https:\/\/doi.org\/10.1177\/1352458520946017","journal-title":"Mult Scler J"},{"issue":"6","key":"14124_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-025-01182-8","volume":"39","author":"BAC Cree","year":"2025","unstructured":"Cree BAC, Berger JR, Greenberg B (2025) The evolution of anti-CD20 treatment for multiple sclerosis: optimization of antibody characteristics and function. CNS Drugs 39(6):545\u2013564. https:\/\/doi.org\/10.1007\/s40263-025-01182-8","journal-title":"CNS Drugs"},{"key":"14124_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.814064","volume":"13","author":"JB Torres","year":"2022","unstructured":"Torres JB, Roodselaar J, Sealey M et al (2022) Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol 13:814064. https:\/\/doi.org\/10.3389\/fimmu.2022.814064","journal-title":"Front Immunol"},{"issue":"1","key":"14124_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Sch\u00e4fer W et al (2013) Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 5(1):22\u201333. https:\/\/doi.org\/10.4161\/mabs.22771","journal-title":"MAbs"},{"issue":"3","key":"14124_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ana.27143","volume":"97","author":"SG Meuth","year":"2025","unstructured":"Meuth SG, Wolff S, M\u00fcck A et al (2025) Different treatment outcomes of multiple sclerosis patients receiving ocrelizumab or ofatumumab. Ann Neurol 97(3):583\u2013595. https:\/\/doi.org\/10.1002\/ana.27143","journal-title":"Ann Neurol"},{"issue":"2","key":"14124_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","volume":"57","author":"P Lee","year":"2013","unstructured":"Lee P, Plavina T, Castro A et al (2013) A second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57(2):141\u2013146. https:\/\/doi.org\/10.1016\/j.jcv.2013.02.002","journal-title":"J Clin Virol"},{"issue":"4","key":"14124_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.msard.2014.04.003","volume":"3","author":"F Sangalli","year":"2014","unstructured":"Sangalli F, Moiola L, Ferr\u00e8 L et al (2014) Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. Mult Scler Relat Disord 3(4):520\u2013526. https:\/\/doi.org\/10.1016\/j.msard.2014.04.003","journal-title":"Mult Scler Relat Disord"},{"key":"14124_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419837809","volume":"12","author":"L Prosperini","year":"2019","unstructured":"Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S (2019) Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord 12:1756286419837809. https:\/\/doi.org\/10.1177\/1756286419837809","journal-title":"Ther Adv Neurol Disord"},{"key":"14124_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102107","volume":"41","author":"T Mustonen","year":"2020","unstructured":"Mustonen T, Rauma I, Hartikainen P et al (2020) Corrigendum to \u201cRisk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation\u201d [Multiple Sclerosis and Related Disorders 38 (2020) 101498]. Mult Scler Relat Disord 41:102107. https:\/\/doi.org\/10.1016\/j.msard.2020.102107","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"14124_CR14","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/13524585211044479","volume":"28","author":"A Bar-Or","year":"2022","unstructured":"Bar-Or A, Wiendl H, Montalban X et al (2022) Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler J 28(6):910\u2013924. https:\/\/doi.org\/10.1177\/13524585211044479","journal-title":"Mult Scler J"},{"issue":"6","key":"14124_CR15","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1111\/bcp.14658","volume":"87","author":"E Gibiansky","year":"2021","unstructured":"Gibiansky E, Petry C, Mercier F et al (2021) Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol 87(6):2511\u20132520. https:\/\/doi.org\/10.1111\/bcp.14658","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14124-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:31:23Z","timestamp":1788867083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-14124-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["14124"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14124-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"3 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional ethics committee of IRCCS Ospedale San Raffaele, Milan, Italy and conducted in accordance to the Helsinki Declaration (Fortaleza revision, 2013) and with European and Italian regulations about privacy. Patients gave dedicated informed consent to be included in the Italian Multiple Sclerosis and Related Disorders Register.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VM has nothing to disclose. LM received compensations for speaking activities and\/or for participating to advisory board from Merck, Celgene, Biogen, Sanofi, Novartis, Roche, Alexion, and Amgen. CZ received compensation for speaking activities, and\/or consulting services, from Alexion, AstraZeneca, Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche, and Sanofi. MR has nothing to disclose. LR has nothing to disclose. MM reports grants and personal fees from Sanofi Genzyme, Merck Serono, Roche, Biogen, Amgen, and Novartis. AN has nothing to disclose. IG has nothing to disclose. VV has nothing to disclose. EP has nothing to disclose. MAR received consulting fees from Biogen, Bristol Myers Squibb, Roche; and speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Celgene, Horizon Therapeutics Italy, Merck Serono SpA, Mitsubishi-Tanabe Pharma, Neuraxpharm, Novartis, Roche, Sandoz, and Sanofi. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for\n                      Multiple Sclerosis and Related Disorders\n                      ; and Associate Co-Editor for Europe and Africa for\n                      Multiple Sclerosis Journal\n                      . SG received compensation for speaking activities from Bristol Myers Squibb, Novartis, Roche and Merck. MF is the Editor-in-Chief of the\n                      Journal of Neurology\n                      , Associate Editor of\n                      Human Brain Mapping\n                      ,\n                      Neurological Sciences,\n                      and\n                      Radiology\n                      ; received compensation for consulting services from Almirall, Biogen, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Roche, and Sanofi; speaking activities from Amgen, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Chiesi Italia SpA, Eisai, Eli Lilly, Fujirebio, Genzyme, Janssen, Merck, Neopharmed Gentili, Neuraxpharm, Novartis, Novo Nordisk, Roche, Sanofi, and Takeda; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Eli Lilly, GE Healthcare Ltd, Merck, Neuraxpharm, Novartis, Roche, Sandoz, Sanofi, and Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, and Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.","order":2,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"577"}}